High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP Article Swipe
Sukanya Dhar
,
Mohona Chakravarti
,
Nilanjan Ganguly
,
Akata Saha
,
Shayani Dasgupta
,
Saurav Bera
,
Anirban Sarkar
,
Kamalika Roy
,
Juhina Das
,
Avishek Bhuniya
,
Sarbari Ghosh
,
Madhurima Sarkar
,
Srabanti Hajra
,
Saptak Banerjee
,
Chiranjib Pal
,
Bhaskar Saha
,
Kalyan Kusum Mukherjee
,
Rathindranath Baral
,
Anamika Bose
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.3389/fimmu.2023.1303959
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.3389/fimmu.2023.1303959
Introduction Non-Hodgkin Lymphoma (NHL) is a heterogeneous lymphoproliferative malignancy with B cell origin. Combinatorial treatment of rituximab, cyclophsphamide, hydroxydaunorubicin, oncovin, prednisone (R-CHOP) is the standard treatment regimen for NHL, yielding a complete remission (CR) rate of 40-50%. Unfortunately, considerable patients undergo relapse after CR or initial treatment, resulting in poor clinical implications. Patient’s response to chemotherapy varies widely from static disease to cancer recurrence and later is primarily associated with the development of multi-drug resistance (MDR). The immunosuppressive cells within the tumor microenvironment (TME) have become a crucial target for improving the therapy efficacy. However, a better understanding of their involvement is needed for distinctive response of NHL patients after receiving chemotherapy to design more effective front-line treatment algorithms based on reliable predictive biomarkers. Methods Peripheral blood from 61 CD20 + NHL patients before and after chemotherapy was utilized for immunophenotyping by flow-cytometry at different phases of treatment. In-vivo and in-vitro doxorubicin (Dox) resistance models were developed with murine Dalton’s lymphoma and Jurkat/Raji cell-lines respectively and impact of responsible immune cells on generation of drug resistance was studied by RT-PCR, flow-cytometry and colorimetric assays. Gene silencing, ChIP and western blot were performed to explore the involved signaling pathways. Results We observed a strong positive correlation between elevated level of CD33 + CD11b + CD14 + CD15 - monocytic MDSCs (M-MDSC) and MDR in NHL relapse cohorts. We executed the role of M-MDSCs in fostering drug resistance phenomenon in doxorubicin-resistant cancer cells in both in-vitro, in-vivo models. Moreover, in-vitro supplementation of MDSCs in murine and human lymphoma culture augments early expression of MDR phenotypes than culture without MDSCs, correlated well with in-vitro drug efflux and tumor progression. We found that MDSC secreted cytokines IL-6, IL-10, IL-1β are the dominant factors elevating MDR expression in cancer cells, neutralization of MDSC secreted IL-6, IL-10, IL-1β reversed the MDR trait. Moreover, we identified MDSC secreted IL-6/IL-10/IL-1β induced STAT1/STAT3/NF-κβ signaling axis as a targeted cascade to promote early drug resistance in cancer cells. Conclusion Our data suggests that screening patients for high titre of M-MDSCs might be considered as a new potential biomarker and treatment modality in overcoming chemo-resistance in NHL patients.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3389/fimmu.2023.1303959
- https://www.frontiersin.org/articles/10.3389/fimmu.2023.1303959/pdf?isPublishedV2=False
- OA Status
- gold
- Cited By
- 10
- References
- 51
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4390984422
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4390984422Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3389/fimmu.2023.1303959Digital Object Identifier
- Title
-
High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOPWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-01-18Full publication date if available
- Authors
-
Sukanya Dhar, Mohona Chakravarti, Nilanjan Ganguly, Akata Saha, Shayani Dasgupta, Saurav Bera, Anirban Sarkar, Kamalika Roy, Juhina Das, Avishek Bhuniya, Sarbari Ghosh, Madhurima Sarkar, Srabanti Hajra, Saptak Banerjee, Chiranjib Pal, Bhaskar Saha, Kalyan Kusum Mukherjee, Rathindranath Baral, Anamika BoseList of authors in order
- Landing page
-
https://doi.org/10.3389/fimmu.2023.1303959Publisher landing page
- PDF URL
-
https://www.frontiersin.org/articles/10.3389/fimmu.2023.1303959/pdf?isPublishedV2=FalseDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.frontiersin.org/articles/10.3389/fimmu.2023.1303959/pdf?isPublishedV2=FalseDirect OA link when available
- Concepts
-
Medicine, Lymphoma, CHOP, Tumor microenvironment, Cancer research, Immunology, Oncology, Chemotherapy, Cancer, Rituximab, Internal medicineTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
10Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 7, 2024: 3Per-year citation counts (last 5 years)
- References (count)
-
51Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4390984422 |
|---|---|
| doi | https://doi.org/10.3389/fimmu.2023.1303959 |
| ids.doi | https://doi.org/10.3389/fimmu.2023.1303959 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/38304256 |
| ids.openalex | https://openalex.org/W4390984422 |
| fwci | 9.15809907 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D000818 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Animals |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D051379 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Mice |
| mesh[3].qualifier_ui | Q000378 |
| mesh[3].descriptor_ui | D000072737 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | metabolism |
| mesh[3].descriptor_name | Myeloid-Derived Suppressor Cells |
| mesh[4].qualifier_ui | Q000494 |
| mesh[4].descriptor_ui | D000069283 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | pharmacology |
| mesh[4].descriptor_name | Rituximab |
| mesh[5].qualifier_ui | Q000627 |
| mesh[5].descriptor_ui | D000069283 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | therapeutic use |
| mesh[5].descriptor_name | Rituximab |
| mesh[6].qualifier_ui | Q000378 |
| mesh[6].descriptor_ui | D000069283 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | metabolism |
| mesh[6].descriptor_name | Rituximab |
| mesh[7].qualifier_ui | Q000494 |
| mesh[7].descriptor_ui | D014750 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | pharmacology |
| mesh[7].descriptor_name | Vincristine |
| mesh[8].qualifier_ui | Q000627 |
| mesh[8].descriptor_ui | D014750 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | therapeutic use |
| mesh[8].descriptor_name | Vincristine |
| mesh[9].qualifier_ui | Q000378 |
| mesh[9].descriptor_ui | D016753 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | metabolism |
| mesh[9].descriptor_name | Interleukin-10 |
| mesh[10].qualifier_ui | Q000494 |
| mesh[10].descriptor_ui | D011241 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | pharmacology |
| mesh[10].descriptor_name | Prednisone |
| mesh[11].qualifier_ui | Q000627 |
| mesh[11].descriptor_ui | D011241 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | therapeutic use |
| mesh[11].descriptor_name | Prednisone |
| mesh[12].qualifier_ui | Q000378 |
| mesh[12].descriptor_ui | D015850 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | metabolism |
| mesh[12].descriptor_name | Interleukin-6 |
| mesh[13].qualifier_ui | Q000378 |
| mesh[13].descriptor_ui | D009364 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | metabolism |
| mesh[13].descriptor_name | Neoplasm Recurrence, Local |
| mesh[14].qualifier_ui | Q000188 |
| mesh[14].descriptor_ui | D008228 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | drug therapy |
| mesh[14].descriptor_name | Lymphoma, Non-Hodgkin |
| mesh[15].qualifier_ui | Q000378 |
| mesh[15].descriptor_ui | D008228 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | metabolism |
| mesh[15].descriptor_name | Lymphoma, Non-Hodgkin |
| mesh[16].qualifier_ui | Q000494 |
| mesh[16].descriptor_ui | D003520 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | pharmacology |
| mesh[16].descriptor_name | Cyclophosphamide |
| mesh[17].qualifier_ui | Q000627 |
| mesh[17].descriptor_ui | D003520 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | therapeutic use |
| mesh[17].descriptor_name | Cyclophosphamide |
| mesh[18].qualifier_ui | Q000494 |
| mesh[18].descriptor_ui | D004317 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | pharmacology |
| mesh[18].descriptor_name | Doxorubicin |
| mesh[19].qualifier_ui | Q000627 |
| mesh[19].descriptor_ui | D004317 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | therapeutic use |
| mesh[19].descriptor_name | Doxorubicin |
| mesh[20].qualifier_ui | Q000378 |
| mesh[20].descriptor_ui | D004317 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | metabolism |
| mesh[20].descriptor_name | Doxorubicin |
| mesh[21].qualifier_ui | Q000378 |
| mesh[21].descriptor_ui | D008223 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | metabolism |
| mesh[21].descriptor_name | Lymphoma |
| mesh[22].qualifier_ui | Q000378 |
| mesh[22].descriptor_ui | D015415 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | metabolism |
| mesh[22].descriptor_name | Biomarkers |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D018432 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Drug Resistance, Multiple |
| mesh[24].qualifier_ui | Q000502 |
| mesh[24].descriptor_ui | D059016 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | physiology |
| mesh[24].descriptor_name | Tumor Microenvironment |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D006801 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Humans |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D000818 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Animals |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D051379 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Mice |
| mesh[28].qualifier_ui | Q000378 |
| mesh[28].descriptor_ui | D000072737 |
| mesh[28].is_major_topic | True |
| mesh[28].qualifier_name | metabolism |
| mesh[28].descriptor_name | Myeloid-Derived Suppressor Cells |
| mesh[29].qualifier_ui | Q000494 |
| mesh[29].descriptor_ui | D000069283 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | pharmacology |
| mesh[29].descriptor_name | Rituximab |
| mesh[30].qualifier_ui | Q000627 |
| mesh[30].descriptor_ui | D000069283 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | therapeutic use |
| mesh[30].descriptor_name | Rituximab |
| mesh[31].qualifier_ui | Q000378 |
| mesh[31].descriptor_ui | D000069283 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | metabolism |
| mesh[31].descriptor_name | Rituximab |
| mesh[32].qualifier_ui | Q000494 |
| mesh[32].descriptor_ui | D014750 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | pharmacology |
| mesh[32].descriptor_name | Vincristine |
| mesh[33].qualifier_ui | Q000627 |
| mesh[33].descriptor_ui | D014750 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | therapeutic use |
| mesh[33].descriptor_name | Vincristine |
| mesh[34].qualifier_ui | Q000378 |
| mesh[34].descriptor_ui | D016753 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | metabolism |
| mesh[34].descriptor_name | Interleukin-10 |
| mesh[35].qualifier_ui | Q000494 |
| mesh[35].descriptor_ui | D011241 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | pharmacology |
| mesh[35].descriptor_name | Prednisone |
| mesh[36].qualifier_ui | Q000627 |
| mesh[36].descriptor_ui | D011241 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | therapeutic use |
| mesh[36].descriptor_name | Prednisone |
| mesh[37].qualifier_ui | Q000378 |
| mesh[37].descriptor_ui | D015850 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | metabolism |
| mesh[37].descriptor_name | Interleukin-6 |
| mesh[38].qualifier_ui | Q000378 |
| mesh[38].descriptor_ui | D009364 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | metabolism |
| mesh[38].descriptor_name | Neoplasm Recurrence, Local |
| mesh[39].qualifier_ui | Q000188 |
| mesh[39].descriptor_ui | D008228 |
| mesh[39].is_major_topic | True |
| mesh[39].qualifier_name | drug therapy |
| mesh[39].descriptor_name | Lymphoma, Non-Hodgkin |
| mesh[40].qualifier_ui | Q000378 |
| mesh[40].descriptor_ui | D008228 |
| mesh[40].is_major_topic | True |
| mesh[40].qualifier_name | metabolism |
| mesh[40].descriptor_name | Lymphoma, Non-Hodgkin |
| mesh[41].qualifier_ui | Q000494 |
| mesh[41].descriptor_ui | D003520 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | pharmacology |
| mesh[41].descriptor_name | Cyclophosphamide |
| mesh[42].qualifier_ui | Q000627 |
| mesh[42].descriptor_ui | D003520 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | therapeutic use |
| mesh[42].descriptor_name | Cyclophosphamide |
| mesh[43].qualifier_ui | Q000494 |
| mesh[43].descriptor_ui | D004317 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | pharmacology |
| mesh[43].descriptor_name | Doxorubicin |
| mesh[44].qualifier_ui | Q000627 |
| mesh[44].descriptor_ui | D004317 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | therapeutic use |
| mesh[44].descriptor_name | Doxorubicin |
| mesh[45].qualifier_ui | Q000378 |
| mesh[45].descriptor_ui | D004317 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | metabolism |
| mesh[45].descriptor_name | Doxorubicin |
| mesh[46].qualifier_ui | Q000378 |
| mesh[46].descriptor_ui | D008223 |
| mesh[46].is_major_topic | True |
| mesh[46].qualifier_name | metabolism |
| mesh[46].descriptor_name | Lymphoma |
| mesh[47].qualifier_ui | Q000378 |
| mesh[47].descriptor_ui | D015415 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | metabolism |
| mesh[47].descriptor_name | Biomarkers |
| mesh[48].qualifier_ui | |
| mesh[48].descriptor_ui | D018432 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | |
| mesh[48].descriptor_name | Drug Resistance, Multiple |
| mesh[49].qualifier_ui | Q000502 |
| mesh[49].descriptor_ui | D059016 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | physiology |
| mesh[49].descriptor_name | Tumor Microenvironment |
| type | article |
| title | High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP |
| biblio.issue | |
| biblio.volume | 14 |
| biblio.last_page | 1303959 |
| biblio.first_page | 1303959 |
| topics[0].id | https://openalex.org/T10185 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9988999962806702 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2734 |
| topics[0].subfield.display_name | Pathology and Forensic Medicine |
| topics[0].display_name | Lymphoma Diagnosis and Treatment |
| topics[1].id | https://openalex.org/T11313 |
| topics[1].field.id | https://openalex.org/fields/24 |
| topics[1].field.display_name | Immunology and Microbiology |
| topics[1].score | 0.9983999729156494 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2403 |
| topics[1].subfield.display_name | Immunology |
| topics[1].display_name | Immune cells in cancer |
| topics[2].id | https://openalex.org/T11020 |
| topics[2].field.id | https://openalex.org/fields/24 |
| topics[2].field.display_name | Immunology and Microbiology |
| topics[2].score | 0.996999979019165 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2403 |
| topics[2].subfield.display_name | Immunology |
| topics[2].display_name | Immune Cell Function and Interaction |
| is_xpac | False |
| apc_list.value | 2950 |
| apc_list.currency | USD |
| apc_list.value_usd | 2950 |
| apc_paid.value | 2950 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2950 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.6706569194793701 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2779338263 |
| concepts[1].level | 2 |
| concepts[1].score | 0.5984146595001221 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q208414 |
| concepts[1].display_name | Lymphoma |
| concepts[2].id | https://openalex.org/C2779725641 |
| concepts[2].level | 3 |
| concepts[2].score | 0.49225297570228577 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q1076228 |
| concepts[2].display_name | CHOP |
| concepts[3].id | https://openalex.org/C2776107976 |
| concepts[3].level | 3 |
| concepts[3].score | 0.49109697341918945 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1786433 |
| concepts[3].display_name | Tumor microenvironment |
| concepts[4].id | https://openalex.org/C502942594 |
| concepts[4].level | 1 |
| concepts[4].score | 0.48483359813690186 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[4].display_name | Cancer research |
| concepts[5].id | https://openalex.org/C203014093 |
| concepts[5].level | 1 |
| concepts[5].score | 0.46841850876808167 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[5].display_name | Immunology |
| concepts[6].id | https://openalex.org/C143998085 |
| concepts[6].level | 1 |
| concepts[6].score | 0.4623066186904907 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[6].display_name | Oncology |
| concepts[7].id | https://openalex.org/C2776694085 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4332043528556824 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[7].display_name | Chemotherapy |
| concepts[8].id | https://openalex.org/C121608353 |
| concepts[8].level | 2 |
| concepts[8].score | 0.42756152153015137 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[8].display_name | Cancer |
| concepts[9].id | https://openalex.org/C2780653079 |
| concepts[9].level | 3 |
| concepts[9].score | 0.41798123717308044 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q412323 |
| concepts[9].display_name | Rituximab |
| concepts[10].id | https://openalex.org/C126322002 |
| concepts[10].level | 1 |
| concepts[10].score | 0.40299472212791443 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[10].display_name | Internal medicine |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.6706569194793701 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/lymphoma |
| keywords[1].score | 0.5984146595001221 |
| keywords[1].display_name | Lymphoma |
| keywords[2].id | https://openalex.org/keywords/chop |
| keywords[2].score | 0.49225297570228577 |
| keywords[2].display_name | CHOP |
| keywords[3].id | https://openalex.org/keywords/tumor-microenvironment |
| keywords[3].score | 0.49109697341918945 |
| keywords[3].display_name | Tumor microenvironment |
| keywords[4].id | https://openalex.org/keywords/cancer-research |
| keywords[4].score | 0.48483359813690186 |
| keywords[4].display_name | Cancer research |
| keywords[5].id | https://openalex.org/keywords/immunology |
| keywords[5].score | 0.46841850876808167 |
| keywords[5].display_name | Immunology |
| keywords[6].id | https://openalex.org/keywords/oncology |
| keywords[6].score | 0.4623066186904907 |
| keywords[6].display_name | Oncology |
| keywords[7].id | https://openalex.org/keywords/chemotherapy |
| keywords[7].score | 0.4332043528556824 |
| keywords[7].display_name | Chemotherapy |
| keywords[8].id | https://openalex.org/keywords/cancer |
| keywords[8].score | 0.42756152153015137 |
| keywords[8].display_name | Cancer |
| keywords[9].id | https://openalex.org/keywords/rituximab |
| keywords[9].score | 0.41798123717308044 |
| keywords[9].display_name | Rituximab |
| keywords[10].id | https://openalex.org/keywords/internal-medicine |
| keywords[10].score | 0.40299472212791443 |
| keywords[10].display_name | Internal medicine |
| language | en |
| locations[0].id | doi:10.3389/fimmu.2023.1303959 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2595292759 |
| locations[0].source.issn | 1664-3224 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1664-3224 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Frontiers in Immunology |
| locations[0].source.host_organization | https://openalex.org/P4310320527 |
| locations[0].source.host_organization_name | Frontiers Media |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320527 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1303959/pdf?isPublishedV2=False |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Frontiers in Immunology |
| locations[0].landing_page_url | https://doi.org/10.3389/fimmu.2023.1303959 |
| locations[1].id | pmid:38304256 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Frontiers in immunology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/38304256 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:10831358 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | cc-by |
| locations[2].pdf_url | https://pmc.ncbi.nlm.nih.gov/articles/PMC10831358/pdf/fimmu-14-1303959.pdf |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/cc-by |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Front Immunol |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/10831358 |
| locations[3].id | pmh:oai:doaj.org/article:a75d2feccb1c409f8d704d295c8d36e8 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306401280 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[3].source.host_organization | |
| locations[3].source.host_organization_name | |
| locations[3].source.host_organization_lineage | |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | article |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Frontiers in Immunology, Vol 14 (2024) |
| locations[3].landing_page_url | https://doaj.org/article/a75d2feccb1c409f8d704d295c8d36e8 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5071238116 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-5942-0590 |
| authorships[0].author.display_name | Sukanya Dhar |
| authorships[0].countries | IN |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I2802271162 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[0].institutions[0].id | https://openalex.org/I2802271162 |
| authorships[0].institutions[0].ror | https://ror.org/02b1bn727 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I2802271162 |
| authorships[0].institutions[0].country_code | IN |
| authorships[0].institutions[0].display_name | Chittaranjan National Cancer Institute |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Sukanya Dhar |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[1].author.id | https://openalex.org/A5088178787 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-7497-4065 |
| authorships[1].author.display_name | Mohona Chakravarti |
| authorships[1].countries | IN |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I2802271162 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[1].institutions[0].id | https://openalex.org/I2802271162 |
| authorships[1].institutions[0].ror | https://ror.org/02b1bn727 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I2802271162 |
| authorships[1].institutions[0].country_code | IN |
| authorships[1].institutions[0].display_name | Chittaranjan National Cancer Institute |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Mohona Chakravarti |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[2].author.id | https://openalex.org/A5056616098 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-7260-1601 |
| authorships[2].author.display_name | Nilanjan Ganguly |
| authorships[2].countries | IN |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I2802271162 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[2].institutions[0].id | https://openalex.org/I2802271162 |
| authorships[2].institutions[0].ror | https://ror.org/02b1bn727 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I2802271162 |
| authorships[2].institutions[0].country_code | IN |
| authorships[2].institutions[0].display_name | Chittaranjan National Cancer Institute |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Nilanjan Ganguly |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[3].author.id | https://openalex.org/A5019423992 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-3125-2871 |
| authorships[3].author.display_name | Akata Saha |
| authorships[3].countries | IN |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I2802271162 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[3].institutions[0].id | https://openalex.org/I2802271162 |
| authorships[3].institutions[0].ror | https://ror.org/02b1bn727 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I2802271162 |
| authorships[3].institutions[0].country_code | IN |
| authorships[3].institutions[0].display_name | Chittaranjan National Cancer Institute |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Akata Saha |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[4].author.id | https://openalex.org/A5044581348 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-9718-6029 |
| authorships[4].author.display_name | Shayani Dasgupta |
| authorships[4].countries | IN |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I2802271162 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[4].institutions[0].id | https://openalex.org/I2802271162 |
| authorships[4].institutions[0].ror | https://ror.org/02b1bn727 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I2802271162 |
| authorships[4].institutions[0].country_code | IN |
| authorships[4].institutions[0].display_name | Chittaranjan National Cancer Institute |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Shayani Dasgupta |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[5].author.id | https://openalex.org/A5007406433 |
| authorships[5].author.orcid | https://orcid.org/0009-0007-9373-4271 |
| authorships[5].author.display_name | Saurav Bera |
| authorships[5].countries | IN |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I2802271162 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[5].institutions[0].id | https://openalex.org/I2802271162 |
| authorships[5].institutions[0].ror | https://ror.org/02b1bn727 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I2802271162 |
| authorships[5].institutions[0].country_code | IN |
| authorships[5].institutions[0].display_name | Chittaranjan National Cancer Institute |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Saurav Bera |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[6].author.id | https://openalex.org/A5031892892 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-5771-8652 |
| authorships[6].author.display_name | Anirban Sarkar |
| authorships[6].countries | IN |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I2802271162 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[6].institutions[0].id | https://openalex.org/I2802271162 |
| authorships[6].institutions[0].ror | https://ror.org/02b1bn727 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I2802271162 |
| authorships[6].institutions[0].country_code | IN |
| authorships[6].institutions[0].display_name | Chittaranjan National Cancer Institute |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Anirban Sarkar |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[7].author.id | https://openalex.org/A5063770684 |
| authorships[7].author.orcid | https://orcid.org/0009-0008-0417-694X |
| authorships[7].author.display_name | Kamalika Roy |
| authorships[7].countries | IN |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I55862774 |
| authorships[7].affiliations[0].raw_affiliation_string | Cellular Immunology and Experimental Therapeutics Laboratory, Department of Zoology, West Bengal State University, Barasat, India |
| authorships[7].institutions[0].id | https://openalex.org/I55862774 |
| authorships[7].institutions[0].ror | https://ror.org/04qs5en05 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I55862774 |
| authorships[7].institutions[0].country_code | IN |
| authorships[7].institutions[0].display_name | West Bengal State University |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Kamalika Roy |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Cellular Immunology and Experimental Therapeutics Laboratory, Department of Zoology, West Bengal State University, Barasat, India |
| authorships[8].author.id | https://openalex.org/A5072359465 |
| authorships[8].author.orcid | https://orcid.org/0009-0000-0377-2944 |
| authorships[8].author.display_name | Juhina Das |
| authorships[8].countries | IN |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I2802271162 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[8].institutions[0].id | https://openalex.org/I2802271162 |
| authorships[8].institutions[0].ror | https://ror.org/02b1bn727 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I2802271162 |
| authorships[8].institutions[0].country_code | IN |
| authorships[8].institutions[0].display_name | Chittaranjan National Cancer Institute |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Juhina Das |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[9].author.id | https://openalex.org/A5004218012 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-6253-0400 |
| authorships[9].author.display_name | Avishek Bhuniya |
| authorships[9].countries | IN |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I2802271162 |
| authorships[9].affiliations[0].raw_affiliation_string | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[9].institutions[0].id | https://openalex.org/I2802271162 |
| authorships[9].institutions[0].ror | https://ror.org/02b1bn727 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I2802271162 |
| authorships[9].institutions[0].country_code | IN |
| authorships[9].institutions[0].display_name | Chittaranjan National Cancer Institute |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Avishek Bhuniya |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[10].author.id | https://openalex.org/A5101499437 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-3192-281X |
| authorships[10].author.display_name | Sarbari Ghosh |
| authorships[10].countries | IN |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I2802271162 |
| authorships[10].affiliations[0].raw_affiliation_string | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[10].institutions[0].id | https://openalex.org/I2802271162 |
| authorships[10].institutions[0].ror | https://ror.org/02b1bn727 |
| authorships[10].institutions[0].type | healthcare |
| authorships[10].institutions[0].lineage | https://openalex.org/I2802271162 |
| authorships[10].institutions[0].country_code | IN |
| authorships[10].institutions[0].display_name | Chittaranjan National Cancer Institute |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Sarbari Ghosh |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[11].author.id | https://openalex.org/A5084918032 |
| authorships[11].author.orcid | https://orcid.org/0000-0001-5419-5219 |
| authorships[11].author.display_name | Madhurima Sarkar |
| authorships[11].countries | IN |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I2802271162 |
| authorships[11].affiliations[0].raw_affiliation_string | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[11].institutions[0].id | https://openalex.org/I2802271162 |
| authorships[11].institutions[0].ror | https://ror.org/02b1bn727 |
| authorships[11].institutions[0].type | healthcare |
| authorships[11].institutions[0].lineage | https://openalex.org/I2802271162 |
| authorships[11].institutions[0].country_code | IN |
| authorships[11].institutions[0].display_name | Chittaranjan National Cancer Institute |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Madhurima Sarkar |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[12].author.id | https://openalex.org/A5114119494 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Srabanti Hajra |
| authorships[12].countries | IN |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I2802271162 |
| authorships[12].affiliations[0].raw_affiliation_string | Department of Pathology, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[12].institutions[0].id | https://openalex.org/I2802271162 |
| authorships[12].institutions[0].ror | https://ror.org/02b1bn727 |
| authorships[12].institutions[0].type | healthcare |
| authorships[12].institutions[0].lineage | https://openalex.org/I2802271162 |
| authorships[12].institutions[0].country_code | IN |
| authorships[12].institutions[0].display_name | Chittaranjan National Cancer Institute |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Srabanti Hajra |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Department of Pathology, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[13].author.id | https://openalex.org/A5027983316 |
| authorships[13].author.orcid | https://orcid.org/0000-0001-9211-2074 |
| authorships[13].author.display_name | Saptak Banerjee |
| authorships[13].countries | IN |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I2802271162 |
| authorships[13].affiliations[0].raw_affiliation_string | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[13].institutions[0].id | https://openalex.org/I2802271162 |
| authorships[13].institutions[0].ror | https://ror.org/02b1bn727 |
| authorships[13].institutions[0].type | healthcare |
| authorships[13].institutions[0].lineage | https://openalex.org/I2802271162 |
| authorships[13].institutions[0].country_code | IN |
| authorships[13].institutions[0].display_name | Chittaranjan National Cancer Institute |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Saptak Banerjee |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[14].author.id | https://openalex.org/A5083860067 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-0724-5292 |
| authorships[14].author.display_name | Chiranjib Pal |
| authorships[14].countries | IN |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I55862774 |
| authorships[14].affiliations[0].raw_affiliation_string | Cellular Immunology and Experimental Therapeutics Laboratory, Department of Zoology, West Bengal State University, Barasat, India |
| authorships[14].institutions[0].id | https://openalex.org/I55862774 |
| authorships[14].institutions[0].ror | https://ror.org/04qs5en05 |
| authorships[14].institutions[0].type | education |
| authorships[14].institutions[0].lineage | https://openalex.org/I55862774 |
| authorships[14].institutions[0].country_code | IN |
| authorships[14].institutions[0].display_name | West Bengal State University |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Chiranjib Pal |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Cellular Immunology and Experimental Therapeutics Laboratory, Department of Zoology, West Bengal State University, Barasat, India |
| authorships[15].author.id | https://openalex.org/A5024742527 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-5833-7912 |
| authorships[15].author.display_name | Bhaskar Saha |
| authorships[15].countries | IN |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I4210104670 |
| authorships[15].affiliations[0].raw_affiliation_string | Department of Pathogenesis and Cell Responses, National Centre for Cell Science, Pune, Maharashtra, India |
| authorships[15].institutions[0].id | https://openalex.org/I4210104670 |
| authorships[15].institutions[0].ror | https://ror.org/01bp81r18 |
| authorships[15].institutions[0].type | facility |
| authorships[15].institutions[0].lineage | https://openalex.org/I2799351866, https://openalex.org/I4210104670, https://openalex.org/I4210134808 |
| authorships[15].institutions[0].country_code | IN |
| authorships[15].institutions[0].display_name | National Centre for Cell Science |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Bhaskar Saha |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Department of Pathogenesis and Cell Responses, National Centre for Cell Science, Pune, Maharashtra, India |
| authorships[16].author.id | https://openalex.org/A5112880190 |
| authorships[16].author.orcid | |
| authorships[16].author.display_name | Kalyan Kusum Mukherjee |
| authorships[16].countries | IN |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I2802271162 |
| authorships[16].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[16].institutions[0].id | https://openalex.org/I2802271162 |
| authorships[16].institutions[0].ror | https://ror.org/02b1bn727 |
| authorships[16].institutions[0].type | healthcare |
| authorships[16].institutions[0].lineage | https://openalex.org/I2802271162 |
| authorships[16].institutions[0].country_code | IN |
| authorships[16].institutions[0].display_name | Chittaranjan National Cancer Institute |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Kalyan Kusum Mukherjee |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Department of Medical Oncology, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[17].author.id | https://openalex.org/A5082768046 |
| authorships[17].author.orcid | https://orcid.org/0000-0002-5589-2646 |
| authorships[17].author.display_name | Rathindranath Baral |
| authorships[17].countries | IN |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I2802271162 |
| authorships[17].affiliations[0].raw_affiliation_string | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[17].institutions[0].id | https://openalex.org/I2802271162 |
| authorships[17].institutions[0].ror | https://ror.org/02b1bn727 |
| authorships[17].institutions[0].type | healthcare |
| authorships[17].institutions[0].lineage | https://openalex.org/I2802271162 |
| authorships[17].institutions[0].country_code | IN |
| authorships[17].institutions[0].display_name | Chittaranjan National Cancer Institute |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Rathindranath Baral |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[18].author.id | https://openalex.org/A5086172980 |
| authorships[18].author.orcid | https://orcid.org/0000-0003-2241-2033 |
| authorships[18].author.display_name | Anamika Bose |
| authorships[18].countries | IN |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I2802271162 |
| authorships[18].affiliations[0].raw_affiliation_string | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| authorships[18].institutions[0].id | https://openalex.org/I2802271162 |
| authorships[18].institutions[0].ror | https://ror.org/02b1bn727 |
| authorships[18].institutions[0].type | healthcare |
| authorships[18].institutions[0].lineage | https://openalex.org/I2802271162 |
| authorships[18].institutions[0].country_code | IN |
| authorships[18].institutions[0].display_name | Chittaranjan National Cancer Institute |
| authorships[18].author_position | last |
| authorships[18].raw_author_name | Anamika Bose |
| authorships[18].is_corresponding | True |
| authorships[18].raw_affiliation_strings | Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1303959/pdf?isPublishedV2=False |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10185 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9988999962806702 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2734 |
| primary_topic.subfield.display_name | Pathology and Forensic Medicine |
| primary_topic.display_name | Lymphoma Diagnosis and Treatment |
| related_works | https://openalex.org/W2411583971, https://openalex.org/W2781286807, https://openalex.org/W31297289, https://openalex.org/W4251119054, https://openalex.org/W3082504439, https://openalex.org/W2265981062, https://openalex.org/W152659163, https://openalex.org/W2360588610, https://openalex.org/W2395776860, https://openalex.org/W1986862727 |
| cited_by_count | 10 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 7 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 3 |
| locations_count | 4 |
| best_oa_location.id | doi:10.3389/fimmu.2023.1303959 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2595292759 |
| best_oa_location.source.issn | 1664-3224 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1664-3224 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Frontiers in Immunology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320527 |
| best_oa_location.source.host_organization_name | Frontiers Media |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1303959/pdf?isPublishedV2=False |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Frontiers in Immunology |
| best_oa_location.landing_page_url | https://doi.org/10.3389/fimmu.2023.1303959 |
| primary_location.id | doi:10.3389/fimmu.2023.1303959 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2595292759 |
| primary_location.source.issn | 1664-3224 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1664-3224 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Frontiers in Immunology |
| primary_location.source.host_organization | https://openalex.org/P4310320527 |
| primary_location.source.host_organization_name | Frontiers Media |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1303959/pdf?isPublishedV2=False |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Frontiers in Immunology |
| primary_location.landing_page_url | https://doi.org/10.3389/fimmu.2023.1303959 |
| publication_date | 2024-01-18 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W1970884884, https://openalex.org/W2072646319, https://openalex.org/W2108131857, https://openalex.org/W1777323899, https://openalex.org/W2239810334, https://openalex.org/W2318772898, https://openalex.org/W68258772, https://openalex.org/W1924320258, https://openalex.org/W1977731244, https://openalex.org/W2117692326, https://openalex.org/W2105565011, https://openalex.org/W2012405690, https://openalex.org/W1976310228, https://openalex.org/W2095868502, https://openalex.org/W2051838890, https://openalex.org/W2101996346, https://openalex.org/W2013575415, https://openalex.org/W3046152640, https://openalex.org/W1567450894, https://openalex.org/W6680687739, https://openalex.org/W2099540110, https://openalex.org/W2073704223, https://openalex.org/W2013485244, https://openalex.org/W1550250208, https://openalex.org/W4308834893, https://openalex.org/W2744261860, https://openalex.org/W1927075449, https://openalex.org/W2331379608, https://openalex.org/W3177202607, https://openalex.org/W3119068311, https://openalex.org/W2120407692, https://openalex.org/W1966577330, https://openalex.org/W2078447740, https://openalex.org/W2965237299, https://openalex.org/W2126503106, https://openalex.org/W2568946517, https://openalex.org/W2118278569, https://openalex.org/W3202545704, https://openalex.org/W2130870648, https://openalex.org/W2163825883, https://openalex.org/W2847139828, https://openalex.org/W2769426045, https://openalex.org/W2132505211, https://openalex.org/W2139580063, https://openalex.org/W2969505681, https://openalex.org/W2133495780, https://openalex.org/W1977681992, https://openalex.org/W2044227662, https://openalex.org/W2006067481, https://openalex.org/W2128609469, https://openalex.org/W2794376169 |
| referenced_works_count | 51 |
| abstract_inverted_index.+ | 130, 210, 212, 214 |
| abstract_inverted_index.- | 216 |
| abstract_inverted_index.B | 10 |
| abstract_inverted_index.a | 5, 30, 86, 95, 201, 317, 344 |
| abstract_inverted_index.61 | 128 |
| abstract_inverted_index.CR | 43 |
| abstract_inverted_index.We | 199, 226, 276 |
| abstract_inverted_index.as | 316, 343 |
| abstract_inverted_index.at | 143 |
| abstract_inverted_index.be | 341 |
| abstract_inverted_index.by | 141, 178 |
| abstract_inverted_index.in | 48, 222, 232, 237, 241, 251, 292, 325, 351, 354 |
| abstract_inverted_index.is | 4, 22, 66, 101 |
| abstract_inverted_index.of | 15, 35, 72, 98, 106, 146, 167, 173, 208, 230, 249, 260, 296, 338 |
| abstract_inverted_index.on | 120, 171 |
| abstract_inverted_index.or | 44 |
| abstract_inverted_index.to | 54, 61, 112, 192, 320 |
| abstract_inverted_index.we | 307 |
| abstract_inverted_index.MDR | 221, 261, 290, 304 |
| abstract_inverted_index.NHL | 107, 131, 223, 355 |
| abstract_inverted_index.Our | 329 |
| abstract_inverted_index.The | 76 |
| abstract_inverted_index.and | 64, 134, 149, 161, 165, 181, 187, 220, 253, 273, 348 |
| abstract_inverted_index.are | 285 |
| abstract_inverted_index.for | 27, 89, 103, 139, 335 |
| abstract_inverted_index.new | 345 |
| abstract_inverted_index.the | 23, 70, 80, 91, 194, 228, 286, 303 |
| abstract_inverted_index.was | 137, 176 |
| abstract_inverted_index.(CR) | 33 |
| abstract_inverted_index.CD14 | 213 |
| abstract_inverted_index.CD15 | 215 |
| abstract_inverted_index.CD20 | 129 |
| abstract_inverted_index.CD33 | 209 |
| abstract_inverted_index.ChIP | 186 |
| abstract_inverted_index.Gene | 184 |
| abstract_inverted_index.MDSC | 279, 297, 309 |
| abstract_inverted_index.NHL, | 28 |
| abstract_inverted_index.axis | 315 |
| abstract_inverted_index.blot | 189 |
| abstract_inverted_index.both | 242 |
| abstract_inverted_index.cell | 11 |
| abstract_inverted_index.data | 330 |
| abstract_inverted_index.drug | 174, 234, 271, 323 |
| abstract_inverted_index.from | 58, 127 |
| abstract_inverted_index.have | 84 |
| abstract_inverted_index.high | 336 |
| abstract_inverted_index.more | 114 |
| abstract_inverted_index.poor | 49 |
| abstract_inverted_index.rate | 34 |
| abstract_inverted_index.role | 229 |
| abstract_inverted_index.than | 263 |
| abstract_inverted_index.that | 278, 332 |
| abstract_inverted_index.well | 268 |
| abstract_inverted_index.were | 155, 190 |
| abstract_inverted_index.with | 9, 69, 157, 269 |
| abstract_inverted_index.(Dox) | 152 |
| abstract_inverted_index.(NHL) | 3 |
| abstract_inverted_index.(TME) | 83 |
| abstract_inverted_index.CD11b | 211 |
| abstract_inverted_index.IL-6, | 282, 299 |
| abstract_inverted_index.MDSCs | 218, 250 |
| abstract_inverted_index.after | 42, 109, 135 |
| abstract_inverted_index.based | 119 |
| abstract_inverted_index.blood | 126 |
| abstract_inverted_index.cells | 78, 170, 240 |
| abstract_inverted_index.early | 258, 322 |
| abstract_inverted_index.found | 277 |
| abstract_inverted_index.human | 254 |
| abstract_inverted_index.later | 65 |
| abstract_inverted_index.level | 207 |
| abstract_inverted_index.might | 340 |
| abstract_inverted_index.their | 99 |
| abstract_inverted_index.titre | 337 |
| abstract_inverted_index.tumor | 81, 274 |
| abstract_inverted_index.(MDR). | 75 |
| abstract_inverted_index.IL-10, | 283, 300 |
| abstract_inverted_index.IL-1β | 284, 301 |
| abstract_inverted_index.MDSCs, | 266 |
| abstract_inverted_index.become | 85 |
| abstract_inverted_index.before | 133 |
| abstract_inverted_index.better | 96 |
| abstract_inverted_index.cancer | 62, 239, 293, 326 |
| abstract_inverted_index.cells, | 294 |
| abstract_inverted_index.cells. | 327 |
| abstract_inverted_index.design | 113 |
| abstract_inverted_index.efflux | 272 |
| abstract_inverted_index.immune | 169 |
| abstract_inverted_index.impact | 166 |
| abstract_inverted_index.models | 154 |
| abstract_inverted_index.murine | 158, 252 |
| abstract_inverted_index.needed | 102 |
| abstract_inverted_index.phases | 145 |
| abstract_inverted_index.static | 59 |
| abstract_inverted_index.strong | 202 |
| abstract_inverted_index.target | 88 |
| abstract_inverted_index.trait. | 305 |
| abstract_inverted_index.varies | 56 |
| abstract_inverted_index.widely | 57 |
| abstract_inverted_index.within | 79 |
| abstract_inverted_index.40-50%. | 36 |
| abstract_inverted_index.In-vivo | 148 |
| abstract_inverted_index.M-MDSCs | 231, 339 |
| abstract_inverted_index.Methods | 124 |
| abstract_inverted_index.RT-PCR, | 179 |
| abstract_inverted_index.Results | 198 |
| abstract_inverted_index.assays. | 183 |
| abstract_inverted_index.between | 205 |
| abstract_inverted_index.cascade | 319 |
| abstract_inverted_index.crucial | 87 |
| abstract_inverted_index.culture | 256, 264 |
| abstract_inverted_index.disease | 60 |
| abstract_inverted_index.explore | 193 |
| abstract_inverted_index.factors | 288 |
| abstract_inverted_index.in-vivo | 244 |
| abstract_inverted_index.induced | 312 |
| abstract_inverted_index.initial | 45 |
| abstract_inverted_index.models. | 245 |
| abstract_inverted_index.origin. | 12 |
| abstract_inverted_index.promote | 321 |
| abstract_inverted_index.regimen | 26 |
| abstract_inverted_index.relapse | 41, 224 |
| abstract_inverted_index.studied | 177 |
| abstract_inverted_index.therapy | 92 |
| abstract_inverted_index.undergo | 40 |
| abstract_inverted_index.western | 188 |
| abstract_inverted_index.without | 265 |
| abstract_inverted_index.(M-MDSC) | 219 |
| abstract_inverted_index.(R-CHOP) | 21 |
| abstract_inverted_index.However, | 94 |
| abstract_inverted_index.Lymphoma | 2 |
| abstract_inverted_index.augments | 257 |
| abstract_inverted_index.clinical | 50 |
| abstract_inverted_index.cohorts. | 225 |
| abstract_inverted_index.complete | 31 |
| abstract_inverted_index.dominant | 287 |
| abstract_inverted_index.elevated | 206 |
| abstract_inverted_index.executed | 227 |
| abstract_inverted_index.in-vitro | 150, 247, 270 |
| abstract_inverted_index.involved | 195 |
| abstract_inverted_index.lymphoma | 160, 255 |
| abstract_inverted_index.modality | 350 |
| abstract_inverted_index.observed | 200 |
| abstract_inverted_index.oncovin, | 19 |
| abstract_inverted_index.patients | 39, 108, 132, 334 |
| abstract_inverted_index.positive | 203 |
| abstract_inverted_index.reliable | 121 |
| abstract_inverted_index.response | 53, 105 |
| abstract_inverted_index.reversed | 302 |
| abstract_inverted_index.secreted | 280, 298, 310 |
| abstract_inverted_index.standard | 24 |
| abstract_inverted_index.suggests | 331 |
| abstract_inverted_index.targeted | 318 |
| abstract_inverted_index.utilized | 138 |
| abstract_inverted_index.yielding | 29 |
| abstract_inverted_index.Moreover, | 246, 306 |
| abstract_inverted_index.biomarker | 347 |
| abstract_inverted_index.cytokines | 281 |
| abstract_inverted_index.developed | 156 |
| abstract_inverted_index.different | 144 |
| abstract_inverted_index.effective | 115 |
| abstract_inverted_index.efficacy. | 93 |
| abstract_inverted_index.elevating | 289 |
| abstract_inverted_index.fostering | 233 |
| abstract_inverted_index.improving | 90 |
| abstract_inverted_index.in-vitro, | 243 |
| abstract_inverted_index.monocytic | 217 |
| abstract_inverted_index.pathways. | 197 |
| abstract_inverted_index.patients. | 356 |
| abstract_inverted_index.performed | 191 |
| abstract_inverted_index.potential | 346 |
| abstract_inverted_index.primarily | 67 |
| abstract_inverted_index.receiving | 110 |
| abstract_inverted_index.remission | 32 |
| abstract_inverted_index.resulting | 47 |
| abstract_inverted_index.screening | 333 |
| abstract_inverted_index.signaling | 196, 314 |
| abstract_inverted_index.treatment | 14, 25, 117, 349 |
| abstract_inverted_index.Conclusion | 328 |
| abstract_inverted_index.Dalton’s | 159 |
| abstract_inverted_index.Peripheral | 125 |
| abstract_inverted_index.algorithms | 118 |
| abstract_inverted_index.associated | 68 |
| abstract_inverted_index.cell-lines | 163 |
| abstract_inverted_index.considered | 342 |
| abstract_inverted_index.correlated | 267 |
| abstract_inverted_index.expression | 259, 291 |
| abstract_inverted_index.front-line | 116 |
| abstract_inverted_index.generation | 172 |
| abstract_inverted_index.identified | 308 |
| abstract_inverted_index.malignancy | 8 |
| abstract_inverted_index.multi-drug | 73 |
| abstract_inverted_index.overcoming | 352 |
| abstract_inverted_index.phenomenon | 236 |
| abstract_inverted_index.phenotypes | 262 |
| abstract_inverted_index.predictive | 122 |
| abstract_inverted_index.prednisone | 20 |
| abstract_inverted_index.recurrence | 63 |
| abstract_inverted_index.resistance | 74, 153, 175, 235, 324 |
| abstract_inverted_index.rituximab, | 16 |
| abstract_inverted_index.silencing, | 185 |
| abstract_inverted_index.treatment, | 46 |
| abstract_inverted_index.treatment. | 147 |
| abstract_inverted_index.Jurkat/Raji | 162 |
| abstract_inverted_index.Non-Hodgkin | 1 |
| abstract_inverted_index.Patient’s | 52 |
| abstract_inverted_index.biomarkers. | 123 |
| abstract_inverted_index.correlation | 204 |
| abstract_inverted_index.development | 71 |
| abstract_inverted_index.distinctive | 104 |
| abstract_inverted_index.doxorubicin | 151 |
| abstract_inverted_index.involvement | 100 |
| abstract_inverted_index.responsible | 168 |
| abstract_inverted_index.Introduction | 0 |
| abstract_inverted_index.chemotherapy | 55, 111, 136 |
| abstract_inverted_index.colorimetric | 182 |
| abstract_inverted_index.considerable | 38 |
| abstract_inverted_index.progression. | 275 |
| abstract_inverted_index.respectively | 164 |
| abstract_inverted_index.Combinatorial | 13 |
| abstract_inverted_index.heterogeneous | 6 |
| abstract_inverted_index.implications. | 51 |
| abstract_inverted_index.understanding | 97 |
| abstract_inverted_index.Unfortunately, | 37 |
| abstract_inverted_index.flow-cytometry | 142, 180 |
| abstract_inverted_index.neutralization | 295 |
| abstract_inverted_index.supplementation | 248 |
| abstract_inverted_index.chemo-resistance | 353 |
| abstract_inverted_index.cyclophsphamide, | 17 |
| abstract_inverted_index.microenvironment | 82 |
| abstract_inverted_index.IL-6/IL-10/IL-1β | 311 |
| abstract_inverted_index.immunophenotyping | 140 |
| abstract_inverted_index.immunosuppressive | 77 |
| abstract_inverted_index.STAT1/STAT3/NF-κβ | 313 |
| abstract_inverted_index.lymphoproliferative | 7 |
| abstract_inverted_index.hydroxydaunorubicin, | 18 |
| abstract_inverted_index.doxorubicin-resistant | 238 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 96 |
| corresponding_author_ids | https://openalex.org/A5086172980 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 19 |
| corresponding_institution_ids | https://openalex.org/I2802271162 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8399999737739563 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.9607834 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |